Celgene Launches New Drug Patent Battle Against Dr. Reddy’s

Robert Hugin, chief executive officer of Celgene, speaks at an interview at Bloomberg headquarters in New York, U.S., on Tuesday, May 7th, 2013. Photographer: Peter Foley/Bloomberg

Celgene Corp. has filed a new patent infringement lawsuit against Dr. Reddy’s Laboratories Ltd. in its ongoing bid to fend off generic drugmakers vying to market a copy of its its top-selling cancer drug Revlimid.

The pharmaceutical company filed a complaint in the U.S. District Court for the District of New Jersey alleging that Dr. Reddy’s proposed generic version of Revlimid infringes five more of its patents. Celegne first sued Dr. Reddy’s for allegedly infringing seven patents covering its cancer drug in 2016 in the same court. That case is ongoing.

Investors are keeping a close eye on whether the two companies will settle. Summit, New Jersey-based Celgene’s is facing headwinds as its blockbuster cancer treatment Revlimid is set to lose market exclusivity because its patents on the drug are set to expire starting 2022.

After Dr. Reddy’s and other generic drugmakers sought regulatory approval to manufacture and sell a copy of Revlimid, Celgene sued for patent infringement. Since 2010, Celgene has filed a dozen patent infringement suits relating to Revlimid patents against Natco Pharma Ltd , Cipla Ltd. and Lotus Pharmaceuticals, among other companies, Bloomberg Law data show. Natco and Celgene reached a settlement in 2015.

The case is Celgene Corporation v. Dr. Reddy’s Laboratories, Ltd. (, D.N.J., No. 2:18-cv-06378, Complaint filed 4/12/18.